Belite Bio ADR (BLTE) Reiterated at Buy by Benchmark After Model Update

April 7, 2026 7:46 AM

Benchmark analyst Bruce D. Jackson reiterated a Buy rating and $217.00 price target on Belite Bio, Inc, ADR (NASDAQ: BLTE).The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found